Legend Biotech Corp - ADR Stock News

SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

New Jersey based Legend Biotech announced its Q2 earnings on Monday, reporting $439m of revenues for its only commercial product, the cell therapy Carvykti. Carvykti leads CAR-T therapy sales with strong efficacy and double-digit sequential revenue growth, but Legend only receives a 50% revenue share outside China. Despite >$1bn cash and operational improvements, Legend remains unprofitable, wi...

Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2025 Earnings Conference Call August 11, 2025 8:00 AM ET Company Participants Alan S. Bash - President of CARVYKTI® Caroline LeCates Paul - Associate Director of Investor Relations Jessie Yeung - Interim CFO, Principal Financial Officer & Principal Accounting Officer Mythili Koneru - Chief Medical Officer Ying Huang - CEO & Director Conference Call P...

SOMERSET, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2025 unaudited financial results and key corporate highlights.

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

SOMERSET, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new long-term results from the CARTITUDE-1 study in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. RRMM patients were treated with a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with no mai...

SOMERSET, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new data evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients living with multiple myeloma will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2025 European Hematology ...